Gefitinib-d8
Gefitinib-d8 (ZD1839-d8) is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells[1][2].
Product Specifications
CAS Number
[857091-32-8]
Product Name Alternative
ZD1839-d8
UNSPSC
12352005
Hazard Statement
H302, H315, H318, H351, H360, H373, H401, H410
Target
Autophagy; EGFR
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.42
Solubility
10 mM in DMSO|DMSO : 125mg/mL (ultrasonic)
Smiles
[2H]C1([2H])OC([2H])([2H])C([2H])([2H])N(CCCOC2=CC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=C2OC)C1([2H])[2H]
Molecular Formula
C22H16D8ClFN4O3
Molecular Weight
454.95
Precautions
H302, H315, H318, H351, H360, H373, H401, H410
References & Citations
[1]Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93 (8) :915-23.|[2]Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61 (19) :7184-8.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
